

Recommendations from York and Scarborough Medicines Commissioning Committee October 2016

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Alirocumab – NICE TA TA393 (June 2016)	primary hypercholesterolaemia and mixed dyslipidaemia	Approved as per NICE TA and pending pathway update to clarify fibrate place in therapy	NICE TA393	As per local pathway which is currently undergoing approval. However to note the NICE TA was issued in June, therefore 90 days should have been September.	Red lipid specialist initiation and prescribing	The annual cost of treatment per patient is £4,383 for 75 mg or 150 mg every 2 weeks however a Patient access scheme is available.
Evolocumab – NICE TA394 (June 2016)	primary hypercholesterolaemia and mixed dyslipidaemia	Approved as per NICE TA and pending pathway update to clarify fibrate place in therapy	NICE TA394	As per local pathway which is currently undergoing approval. However to note the NICE TA was issued in June, therefore 90 days should have been September.	Red lipid specialist initiation and prescribing	The annual cost of treatment per patient is about £4,422.60 for 140 mg every 2 weeks, and £6,123.60 for 420 mg monthly however a patient access scheme is available.
Degarelix - NICE TA404	advanced hormone-dependent prostate cancer	Approved as per TA	NICE TA 404	Degarelix is another treatment option in advanced hormone-dependent prostate cancer patients who have spinal metastases. This is a small number of people and clinical practice should not change substantially.	Amber specialist initiation	The cost of 2x120-mg vials is £260.00 and an 80-mg vial is £129.37 however approval is dependent on a rebate being available.
Guanfacine	ADHD	Approved as per ADHD prescribing algorithm	TEWV ADHD algorithm.	Treatment of ADHD in children and adolescents in whom stimulants are not suitable and are not effective.	Red until SCP drafted then to move to Amber specialist	Guanfacine is a substitution not additional therapy and costs are similar to atomoxetine and

					initiation.	lisdexamfetamine which would be tried first.
TA407: Secukinumab	for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	Approved as per NICE guidance	NICE TA 407	To be used in line with NICE following failure with or intolerance to anti-TNFs.	Red	Secukinumab is available at the list price of £609.39 for a 150-mg pre-filled pen or syringe however a patient access scheme is available. As it's being used as a substitution it is unlikely to increase costs.
TA409: Aflibercept	for treating visual impairment caused by macular oedema after branch retinal vein occlusion	Approved as per NICE TA	NICE TA 409	Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme.	Red	The list price of aflibercept is £816 for 1 vial. A patient access scheme is available. Available as an option alongside ranibizumab which is a similar price.
Hypertonic Sodium Chloride	Use in patients aged six years of age and over with a respiratory condition leading to retained bronchopulmonary secretions	Approved	In line with BTS guidelines for bronchiectasis and as per Cochrane review recommendations for CF patients.	Approved where usual treatment (physiotherapy airway clearance, adequate systemic hydration, dornase alpha for those with CF, carbocysteine where indicated) isn't sufficiently effective.	Amber specialist initiation	60 x 4 mL = £27.00
TA406: Crizotinib	for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	NHS England Commissioned	-	-	-	-
TA408: Pegaspargase	for treating acute lymphoblastic leukaemia	NHS England Commissioned	-	-	-	-
TA410: Talimogene laherparepvec	for treating unresectable metastatic melanoma	NHS England Commissioned	-	-	-	-
TA411:	for untreated advanced	NHS England	-	-	-	-

Necitumumab	or metastatic squamous non-small-cell lung cancer	Commissioned				
TA412: Radium-223 dichloride	for treating hormone-relapsed prostate cancer with bone metastases	NHS England Commissioned	-	-	-	-